Category Archives: Setipiprant

Brief Items of Interest, September 2016

Few days later than usual, but lots of new developments in the past month.

Hair loss news first:

— The most important news is courtesy of HLT, which several days ago interviewed people from the Dr. Tsuji/RIKEN/Organ Technologies team (but not Dr. Tsuji himself). Interview publication has been delayed due to Japan’s “Respect for the Aged Day“, but according to the HLT admin, he has been given permission to divulge the following regarding the Tsuji team’s work:

“Human trials to begin 2018. Commercial availability still on track for 2020.”

While not surprising since this is an affirmation of what was said in July of this year, it will hopefully put many people’s minds at ease…at least till early next year:-)

— Thanks to who else but JAK superfan “nasa_rs” for letting us know that Aclaris Therapeutics updated its pipeline page and finally added its topical JAK inhibitor product (ATI-500003) for men with androgenetic alopecia (AGA).  Interestingly, all four of its JAK products are now shown to be 80 percent or so through the pre-clinical phase and are on the verge of entering Phase 1 trials. According to the pdf from the company’s September 14th webcast (see page 26), proof-of-concept (POC = Phase 1 and Phase IIA) trials for the company’s alopecia areata (AA) drugs will commence in the first and second quarter of 2017.  Considering that JAK inhibitors Ruxolitinib and Tofacitinib have already been FDA approved and in use for around 5-6 years, the big question is whether this will allow faster progression of Phase 1 clinical trials for Aclaris’ various JAK products?  According to wikipedia, there are currently seven other JAK inhibitors in clinical trials.

— Long-time perpetual disappointment Follica, which had earlier announced initiation of a registration study in the second half of 2016 has delayed plans till the first half of 2017 (thanks as always to “Mike G”, who sent me that link and has e-mailed me news about Follica many times in the past).  A recently announced best-case product release scenario of 2018 by Follica now sounds just as unlikely as hyper-prolific commentator “mjones” ever meeting with his hero and Follica founder Dr. George Cotsarelis:-(

— In my June “brief items of interest” blog post, I mentioned that Allergan had commenced phase 2A clinical trials for Setipiprant to treat androgenetic alopecia.  The company updated its clinical trial page again in August and many of their centers in the US are currently recruiting volunteers.  It seems like they will even pay you up to $650 for participating.

— Allergan also updated its Bimatoprost clinical trial page in August.  Study is expected to be completed very soon in October 2016.

Follicum updated its website regarding  the second part of their clinical phase I/IIa study for their FOL-005 hair loss product.  I like the fact that they are undertaking some of this work at the reputable Charité-Universitätsmedizin Berlin in Germany.  Follicum also sent out an e-mail to many people (one of whom was myself) and here is the gist of it:

“The study is divided in two parts, a single ascending dose part and a multiple dose part.  Multiple dosing has begun on healthy volunteers.  The study has now finalized recruiting volunteers and is fully recruited, it is being carried out in Germany at: Klinik für Dermatologie, Venerologie und Allergologie, Charité-Universitätsmedizin Berlin, Germany.  As this is a regulated clinical trial results have to be published once the trial is completed and all the results have been analysed, which is estimated to be in January 2017.”

A conference on the Wnt signaling pathway ran from 14th-17th September in the Czech Republic.  Interestingly, Samumed was one of the main sponsors.  Of even more importance, it seems like Samumed made an extremely interesting and well received presentation at the 13th Medical Innovation Summit in London on September 17th 2016.  Why do I say that without seeing the actual presentation?  Because of numerous Tweets praising it…see this blog’s recent Twitter feed and thanks to commentator “Optimism” who notified me of the Twitter praise for Samumed’s presentation.

— The Follicle Thought blog had an extensive interview with HairCell CEO Howard Leonhardt.

— One of the commentators on this forum named “skin” has created a thread on his dermarolling treatment on the Bald Truth forums. He made some interesting comments in this old post of mine that are worth reading, especially if you are considering trying out dermarolling.

Lengthy article on hair loss, including some thoughts from Dr. Claire Higgins.

— Yet another study on the genetics behind hair loss.

Scalp micropigmentation video on Quartz.

Troy Hurtubise wants to cure hair loss.  This is about as far fetched as it will ever get in our already way-out-there hair loss cure world.

— Donald Trump lets Jimmy Fallon mess up his hair:

And now on to medical items of interest:

— Burned firefighter Pat Hardison continues to thrive one year after his face transplant.  Pretty amazing progression via monthly images in here.

— I have covered Zion Harvey 3 times on this blog now.  His 1-year post double hand transplant update video is below. Note that he has also had a kidney transplant and has prosthetic legs too:

— MIT scientist claims that his pill is the one when it comes to the fountain of youth.  Most important (and discouraging for us) quote:

“Guarente has been taking Basis for two years, but it’s a good bet that he is not among those who have observed hair growth as one of the pill’s effects.” 

— World’s formerly fattest man who lost 658 pound after gastric bypass surgery in 2010 will now get a second free surgery to remove excess skin.

— OxSyBio’s 3D “droplet printing” technology creates a tissue-like material that functions just like real cells.

— Embryos from skin cells instead of from eggs?  And of course artificial wombs. Would mean real freedom for both men and women.

Infertile mice give birth due to 3D printed ovaries.

Stem cell therapy restores arm and hand movement for a paralyzed man.

New drug to treat Alzheimer’s could be very effective.

—  Lysyl oxidase inhibition could eliminate scar formation.

Cold plasma to heal wounds.

— CRISPR’d vegetables are now here.

— With Japanese electronics behemoth Kyocera partnering with Tsuji/RIKEN and their cell based work, it is perhaps not surprising that in the US General Electric now aims to build a $1 billion business “offering vital manufacturing tools for a coming wave of cell therapies.

Manufacturing dopamine in the brain with gene therapy.

Dramatic advances in human-on-a-chip technology will likely lead to a significant reduction in animal testing.  As it is, we in the hair loss world have seen almost zero benefit from many decades of research on mice.  These chips are going to be a much better approximation of real human beings in comparison to mice it seems.

Brief Items of Interest, August 2016

Hair loss news first:

Update: Histogen gets funding from China and also targets the Chinese market.

Kyocera updated its article on the biggest news of this year in the hair loss world.  They plan to conduct clinical research in Japanese fiscal year 2019 (i.e., between April 1st 2018 – March 31st 2019) and put the technology into “practical use” in 2020.  Interesting quote:

“While various methods are under evaluation, Kyocera’s piezoelectric technology is of particular interest as a means of discharging small amounts of viscid cells in a precise manner during the cell processing process.”

PGD2 inhibitor Fevipiprant could be a miracle treatment for asthma.  I am still hopeful that Setipiprant will be better than expected when it comes to treating hair loss.  Worth listening to Kythera CEO’s interview here if you haven’t already.

— More evidence that enhancing the β-catenin signalling pathway in dermal papilla cells allows faster and denser hair growth.

— New findings from a Stanford University (US) and A*STAR (Singapore)’s Institute of Medical Biology collaboration:  Wnt signalling plays a critical role in hair follicle stem cell maintenance. Interesting quote:

“Compounds, particularly those which have already been established to be Wnt activators, can now be tested against cultured HFSCs to see if they do stimulate hair regrowth. The scientific community may also be able to culture HFSCs more efficiently by tweaking Wnt signalling to the optimal levels.”

New interview with Replicel CEO Lee Buckler.  Important part is around three minutes in.

— New article that covers Dr. Christiano’s company Rapunzel as well as other relevant subjects including Samumed, Vixen/Aclaris and Dr. Joseph Greco.

— Hairlosstalk is interviewing Dr. Gail Naughton of Histogen this week.  Unfortunately the questions are already finalized, but its still worth a gander through this thread.

— New study from China: “Hair follicle and sebaceous gland “de novo” regeneration with cultured epidermal stem cells and skin-derived precursors.”

Cellmid to enter US hair loss treatment market.

— Dr. Cole’s office sent me an update on PRP and ACell recently.  I think they sent out a mass e-mail on the subject since its contents were also pasted in here.

— Joe Tillman discusses his Dr. Cooley PRP treatment results.

Healeon Medical is starting a new clinical trial in Honduras that will “evaluate the safety and efficacy of the use of a biocellular mixture of emulsified adipose-derived tissue stromal vascular fraction (AD-tSVF) and high density platelet-rich plasma concentrate (HD- PRP) as compared with adipose-derived cell-enriched SVF (AD-cSVF) + AD-tSVF and HD- PRP concentrates in treatment of androgenetic alopecia (AGA) and Female Pattern Hair Loss (FPHL).”

— Dr. Jeffrey Epstein is conducting the “first ever FDA-approved study in the US on the use of fat-derived stems cell for the treatment of hair loss in men and women.”  If you are near Miami, perhaps worth a visit.

On a less serious train of thought:

Eat curry to prevent hair loss.

— He says that black guys do not always pull off the bald look.  I still think he pulls it off.

UK celebrity funnyman divorcee gets a hair transplant to prepare for online dating so as to not look like a thug.

When Homer Simpson got hair due to a miracle drug call dimoxinil.

Our lack of body and scalp hair may have allowed our species to thrive.

And now on to medical items of interest:

— Last year I discussed the inspirational Zion Harvey after he got a double hand transplant.  He had lost both his legs, both his hands and his kidney to a childhood infection.  One year after his double hand transplant surgery, here is the result:

Chinese scientists to pioneer first human CRISPR trial.

— “Bio is the new digital.”  Great article from Taiwan that is a must read after translation.  Boston is to biotech what Silicon Valley is to information technology.  In the hair loss world, it seems like New York and San Diego (see here) are far more important than Boston, but perhaps we will see some surprises from Boston soon?!

— Two stories on aging in the Economist in the past week.  Here and here.

Excellent article on human enhancement.

Dr. David Sinclair’s presentation on ageing and lifespan extension.

— At least androgens have some benefits such as telomere length extension.

Dr. George Church on the future of genetic engineering.

Gene therapy cure with a money-back guarantee.

— Using a patient’s own stem cells and a 3D printer, scientists have genetically engineered a “living hip” that will cease pain.

— Cornea cells successfully grown and implanted to cure blindness in animals.

Peter Thiel is a fan of parabiosis.

Update on Dr. Frankenstein.  Full body transplant scheduled for December 2017.

— Scientists just created nanorobots to travel the bloodstream and fight cancerous tumors.